NASDAQ:KOOL - Cesca Therapeutics Stock Price, Forecast & News

Cesca Therapeutics trades on the NASDAQ under the ticker symbol "KOOL."

Cesca Therapeutics Inc (NASDAQ:KOOL) posted its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative return on equity of 77.30%. View Cesca Therapeutics' Earnings History.

1 brokerages have issued twelve-month price targets for Cesca Therapeutics' shares. Their forecasts range from $7.50 to $7.50. On average, they expect Cesca Therapeutics' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 160.4% from the stock's current price. View Analyst Price Targets for Cesca Therapeutics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cesca Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cesca Therapeutics.

News coverage about KOOL stock has trended neutral this week, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cesca Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Cesca Therapeutics.

Cesca Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totalling 208,500 shares, an increase of 14.1% from the September 15th total of 182,700 shares. Based on an average daily volume of 202,800 shares, the days-to-cover ratio is presently 1.0 days. Approximately 12.1% of the company's shares are short sold. View Cesca Therapeutics' Current Options Chain.

Some companies that are related to Cesca Therapeutics include Kazia Therapeutics (KZIA), Sanara MedTech (SMTI), Mereo BioPharma Group (MPH), Q BioMed (QBIO), Microbot Medical (MBOT), Exopharm (EX1), Biomerica (BMRA), BioNano Genomics (BNGO), Zosano Pharma (ZSAN), BioCardia (BCDA), Sierra Oncology (SRRA), Arrayit (ARYC), Oragenics (OGEN), Neovasc (NVCN) and Soligenix (SNGX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cesca Therapeutics investors own include CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Gilead Sciences (GILD), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI), OncoSec Medical (ONCS), Onconova Therapeutics (ONTX), Synergy Pharmaceuticals (SGYP) and AEterna Zentaris (AEZS).

Shares of KOOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KOOL stock can currently be purchased for approximately $2.88.

Cesca Therapeutics has a market capitalization of $6.97 million and generates $9.67 million in revenue each year. The biotechnology company earns $-39,720,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. Cesca Therapeutics employs 53 workers across the globe.View Additional Information About Cesca Therapeutics.

The official website for Cesca Therapeutics is http://www.cescatherapeutics.com/.

Cesca Therapeutics' mailing address is 2711 CITRUS ROAD, RANCHO CORDOVA CA, 95742. The biotechnology company can be reached via phone at 916-858-5100 or via email at [email protected]